Publication

When EV Dose Is Not What It Seems: Quantitative Mismatch Between Particle Number- and Protein-Based Dosing

Research shows that particle- and protein-based extracellular vesicle dosing are not interchangeable, supporting a multidimensional…

CertaraSeptember 18, 2026

Publication

Population Pharmacokinetic Analyses and Exposure-Efficacy Relationships of Venetoclax in Chinese Pediatric Patients with Hematological Malignancy in a Real-World Setting

Find out how PopPK model links higher venetoclax exposure to MRD-negative status in pediatric AML…

CertaraMarch 20, 2026

Publication

Evaluation of a New Formulation That Improves the Bioavailability and Food Effect of Abiraterone: An Open-Label, Crossover, Randomized, Controlled, Phase I Clinical Trial

Find out how RL001 delivers >1000 mg tablet exposure with reduced food effect and improved…

CertaraJanuary 1, 2026

Publication

Dosing Optimization of Lamotrigine in Peripregnancy Epilepsy Through PopPK Modelling and Simulation

Find out how PopPK modelling shows major gestational changes in lamotrigine clearance and supports precise…

CertaraNovember 20, 2025

Publication

Simulation of perioperative Ibrutinib withdrawal using a population pharmacokinetic model and sparse clinical concentration data.

Explore how Phoenix NLME simulations highlight variability in perioperative ibrutinib exposure and the impact of…

CertaraNovember 20, 2025

Publication

Exploring the Population Pharmacokinetic and Pharmacogenetics Characteristics of Flurbiprofen Isomers in Selective Joint Replacement Patients with Postoperative Pain

Find out how Phoenix NLME identifies pharmacogenetic drivers of flurbiprofen enantiomer clearance and CSF distribution…

CertaraOctober 9, 2025

Publication

Bioequivalence Study of Palbociclib Tablets in Healthy Volunteers

Find out how palbociclib formulations are bioequivalent under fasting and fed conditions using Phoenix WinNonlin

CertaraAugust 18, 2025

Publication

Effect of Food on the Pharmacokinetic Characteristics of a Single Oral Dose of D-1553, a Selective Inhibitor of KRASG12C, in Healthy Chinese Subjects`

Explore how high‑fat meals cause only modest PK changes in D‑1553, supporting administration without regard…

CertaraMarch 18, 2025

Publication

Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT3 Antagonist Antiemetic Drugs.

Discover how ondansetron and granisetron increase unbound platinum exposure versus palonosetron, modelled using Phoenix NLME.

CertaraDecember 22, 2024

Publication

Building vancomycin population pharmacokinetic model for Japanese low birth weight infants in comparing it with previously reported pediatric population pharmacokinetic models.

Learn how LBW‑specific PopPK model improves vancomycin prediction accuracy and supports optimized dosing using Phoenix…

CertaraDecember 11, 2024

Oncology

When EV Dose Is Not What It Seems: Quantitative Mismatch Between Particle Number- and Protein-Based Dosing

Population Pharmacokinetic Analyses and Exposure-Efficacy Relationships of Venetoclax in Chinese Pediatric Patients with Hematological Malignancy in a Real-World Setting

Evaluation of a New Formulation That Improves the Bioavailability and Food Effect of Abiraterone: An Open-Label, Crossover, Randomized, Controlled, Phase I Clinical Trial

Dosing Optimization of Lamotrigine in Peripregnancy Epilepsy Through PopPK Modelling and Simulation

Simulation of perioperative Ibrutinib withdrawal using a population pharmacokinetic model and sparse clinical concentration data.

Exploring the Population Pharmacokinetic and Pharmacogenetics Characteristics of Flurbiprofen Isomers in Selective Joint Replacement Patients with Postoperative Pain

Bioequivalence Study of Palbociclib Tablets in Healthy Volunteers

Effect of Food on the Pharmacokinetic Characteristics of a Single Oral Dose of D-1553, a Selective Inhibitor of KRASG12C, in Healthy Chinese Subjects`

Population Pharmacokinetic Model of Platinum Disposition in Cancer Patients Receiving Cisplatin and Randomized to 5-HT3 Antagonist Antiemetic Drugs.

Building vancomycin population pharmacokinetic model for Japanese low birth weight infants in comparing it with previously reported pediatric population pharmacokinetic models.

Newsletter sign up

Quick links

Solutions

Contact